Shinji Yamazaki

Shinji Yamazaki

UNVERIFIED PROFILE

Are you Shinji Yamazaki?   Register this Author

Register author
Shinji Yamazaki

Shinji Yamazaki

Publications by authors named "Shinji Yamazaki"

Are you Shinji Yamazaki?   Register this Author

42Publications

1489Reads

26Profile Views

Physiologically-Based Pharmacokinetic Modeling Approach to Predict Rifampin-Mediated Intestinal P-Glycoprotein Induction.

CPT Pharmacometrics Syst Pharmacol 2019 Sep 5;8(9):634-642. Epub 2019 Sep 5.

Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, Groton, Connecticut, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/psp4.12458DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6765699PMC
September 2019

Application of Physiologically Based Pharmacokinetic Modeling in Understanding Bosutinib Drug-Drug Interactions: Importance of Intestinal P-Glycoprotein.

Drug Metab Dispos 2018 Aug 8;46(8):1200-1211. Epub 2018 May 8.

Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, San Diego, California (S.Y., C.-M.L.) and Groton, Connecticut (E.K., C.C., M.V.V.).

View Article

Download full-text PDF

Source
http://dmd.aspetjournals.org/lookup/doi/10.1124/dmd.118.0804
Publisher Site
http://dx.doi.org/10.1124/dmd.118.080424DOI Listing
August 2018

Relationships of Changes in Pharmacokinetic Parameters of Substrate Drugs in Drug-Drug Interactions on Metabolizing Enzymes and Transporters.

Authors:
Shinji Yamazaki

J Clin Pharmacol 2018 May 3. Epub 2018 May 3.

Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, San Diego, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcph.1104DOI Listing
May 2018

Application of Physiologically Based Pharmacokinetic Modeling to the Understanding of Bosutinib Pharmacokinetics: Prediction of Drug-Drug and Drug-Disease Interactions.

Drug Metab Dispos 2017 04 6;45(4):390-398. Epub 2017 Feb 6.

Clinical Pharmacology, Pfizer Japan Inc., Tokyo, Japan (C.O.); Clinical Pharmacology, Pfizer Inc., San Diego, California (P.-H.H.); Clinical Pharmacology, Pfizer Essential Health, Collegeville, Pennsylvania (R.A.); and Pharmacokinetics, Dynamics, and Metabolism, Pfizer Worldwide Research and Development, San Diego, California (C.-M.L., S.Y.)

View Article

Download full-text PDF

Source
http://dmd.aspetjournals.org/lookup/doi/10.1124/dmd.116.0744
Publisher Site
http://dx.doi.org/10.1124/dmd.116.074450DOI Listing
April 2017

Found in Translation: Maximizing the Clinical Relevance of Nonclinical Oncology Studies.

Clin Cancer Res 2017 Feb 22;23(4):1080-1090. Epub 2016 Aug 22.

Department of Pharmacokinetics, Dynamics and Metabolism - New Biological Entities, Pfizer Worldwide Research and Development, San Diego, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-16-1164DOI Listing
February 2017

Translational modeling and simulation approaches for molecularly targeted small molecule anticancer agents from bench to bedside.

Expert Opin Drug Metab Toxicol 2016 ;12(3):253-65

a Pharmacokinetics, Dynamics & Metabolism , Pfizer Worldwide Research & Development , San Diego , CA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/17425255.2016.1141895DOI Listing
October 2016

Prediction of Drug-Drug Interactions with Crizotinib as the CYP3A Substrate Using a Physiologically Based Pharmacokinetic Model.

Drug Metab Dispos 2015 Oct 15;43(10):1417-29. Epub 2015 Jul 15.

Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research and Development, San Diego, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/dmd.115.064618DOI Listing
October 2015

Mechanistic understanding of translational pharmacokinetic-pharmacodynamic relationships in nonclinical tumor models: a case study of orally available novel inhibitors of anaplastic lymphoma kinase.

Drug Metab Dispos 2015 Jan 27;43(1):54-62. Epub 2014 Oct 27.

Pharmacokinetics, Dynamics and Metabolism (S.Y., J.L.L., P.V.) and Oncology Research Unit (H.Y.Z., H.W., T.S.), Pfizer Worldwide Research & Development, San Diego, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/dmd.114.061143DOI Listing
January 2015

Translational pharmacokinetic-pharmacodynamic modeling for an orally available novel inhibitor of anaplastic lymphoma kinase and c-Ros oncogene 1.

J Pharmacol Exp Ther 2014 Oct 29;351(1):67-76. Epub 2014 Jul 29.

Pharmacokinetics, Dynamics and Metabolism (S.Y., J.L.L., P.V.) and Oncology Research Unit (H.Y.Z., H.W., T.S.), Pfizer Worldwide Research & Development, San Diego, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/jpet.114.217141DOI Listing
October 2014

Application of target-mediated drug disposition model to small molecule heat shock protein 90 inhibitors.

Drug Metab Dispos 2013 Jun 4;41(6):1285-94. Epub 2013 Apr 4.

Pharmacokinetics, Dynamics, and Metabolism, Pfizer Worldwide Research and Development, San Diego, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/dmd.113.051490DOI Listing
June 2013

Translational pharmacokinetic-pharmacodynamic modeling from nonclinical to clinical development: a case study of anticancer drug, crizotinib.

Authors:
Shinji Yamazaki

AAPS J 2013 Apr 19;15(2):354-66. Epub 2012 Dec 19.

Pharmacokinetics, Dynamics and Metabolism, La Jolla Laboratories, Pfizer Worldwide Research & Development, 10777 Science Center Drive, San Diego, CA 92121, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1208/s12248-012-9436-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3675733PMC
April 2013

Prediction of crizotinib-midazolam interaction using the Simcyp population-based simulator: comparison of CYP3A time-dependent inhibition between human liver microsomes versus hepatocytes.

Drug Metab Dispos 2013 Feb 5;41(2):343-52. Epub 2012 Nov 5.

Pharmacokinetics, Dynamics, and Metabolism, Pfizer Worldwide Research and Development, San Diego, CA, USA.

View Article

Download full-text PDF

Source
http://dmd.aspetjournals.org/cgi/doi/10.1124/dmd.112.049114
Publisher Site
http://dx.doi.org/10.1124/dmd.112.049114DOI Listing
February 2013

Epithelial tissue hyperplasia induced by the RAF inhibitor PF-04880594 is attenuated by a clinically well-tolerated dose of the MEK inhibitor PD-0325901.

Mol Cancer Ther 2012 Oct 2;11(10):2274-83. Epub 2012 Jul 2.

Shubha Bagrodia, Oncology Research Unit, Pfizer Worldwide Research and Development, La Jolla Laboratories, 10724 Science Center Drive, San Diego, CA 92121, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-11-0984DOI Listing
October 2012

Pharmacokinetic/pharmacodynamic modeling of crizotinib for anaplastic lymphoma kinase inhibition and antitumor efficacy in human tumor xenograft mouse models.

J Pharmacol Exp Ther 2012 Mar 30;340(3):549-57. Epub 2011 Nov 30.

Pharmacokinetics, Dynamics, and Metabolism, La Jolla Laboratories, Pfizer Worldwide Research and Development, 10777 Science Center Drive, San Diego, CA 92121, USA.

View Article

Download full-text PDF

Source
http://jpet.aspetjournals.org/content/340/3/549.full.pdf
Web Search
http://jpet.aspetjournals.org/cgi/doi/10.1124/jpet.111.18887
Publisher Site
http://dx.doi.org/10.1124/jpet.111.188870DOI Listing
March 2012

Pharmacokinetic-pharmacodynamic modeling of biomarker response and tumor growth inhibition to an orally available heat shock protein 90 inhibitor in a human tumor xenograft mouse model.

J Pharmacol Exp Ther 2011 Sep 16;338(3):964-73. Epub 2011 Jun 16.

Department of Pharmacokinetics, Pfizer Worldwide Research and Development, San Diego, California 92121, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/jpet.111.181339DOI Listing
September 2011

Effective targeting of triple-negative breast cancer cells by PF-4942847, a novel oral inhibitor of Hsp 90.

Clin Cancer Res 2011 Aug 29;17(16):5432-42. Epub 2011 Jun 29.

Oncology Research, Pfizer Worldwide Research and Development, San Diego, California 92121, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-11-0592DOI Listing
August 2011

Prediction of oral pharmacokinetics of cMet kinase inhibitors in humans: physiologically based pharmacokinetic model versus traditional one-compartment model.

Drug Metab Dispos 2011 Mar 23;39(3):383-93. Epub 2010 Nov 23.

Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, San Diego, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/dmd.110.035857DOI Listing
March 2011

Gender specific drug metabolism of PF-02341066 in rats--role of sulfoconjugation.

Curr Drug Metab 2010 May;11(4):296-306

Department of Pharmacokinetics, Dynamics and Metabolism, Pfizer Global Research and Development, San Diego, CA 92121, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/138920010791514207DOI Listing
May 2010

Application of stable isotope methodology in the evaluation of the pharmacokinetics of (S,S)-3-[3-(methylsulfonyl)phenyl]-1-propylpiperidine hydrochloride in rats.

Drug Metab Dispos 2009 May 23;37(5):937-45. Epub 2009 Feb 23.

Pharmacokinetics, Dynamics and Metabolism, La Jolla Laboratories, Pfizer Global Research and Development, 10777 Science Center Dr., San Diego, CA 92121, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/dmd.108.025478DOI Listing
May 2009

Pharmacokinetic-pharmacodynamic modeling of biomarker response and tumor growth inhibition to an orally available cMet kinase inhibitor in human tumor xenograft mouse models.

Drug Metab Dispos 2008 Jul 1;36(7):1267-74. Epub 2008 Apr 1.

Pharmacokinetics, Dynamics and Metabolism, La Jolla Laboratories, Pfizer Global Research and Development, 10777 Science Center Dr., San Diego, CA 92121, USA.

View Article

Download full-text PDF

Source
http://dmd.aspetjournals.org/cgi/doi/10.1124/dmd.107.019711
Publisher Site
http://dx.doi.org/10.1124/dmd.107.019711DOI Listing
July 2008

Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma.

Mol Cancer Ther 2007 Dec;6(12 Pt 1):3314-22

Department of Cancer Biology, Pfizer Global Research and Development, La Jolla Laboratories, 10724 Science Center Drive, La Jolla, CA 92121, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-07-0365DOI Listing
December 2007

Comparison of prediction methods for in vivo clearance of (S,S)-3-[3-(methylsulfonyl)phenyl]-1-propylpiperidine hydrochloride, a dopamine D2 receptor antagonist, in humans.

Drug Metab Dispos 2004 Apr;32(4):398-404

Pharmacokinetics, Dynamics and Metabolism, La Jolla Laboratories, Pfizer Inc., 10724 Science Center Drive, San Diego, CA 92121, USA.

View Article

Download full-text PDF

Source
http://dmd.aspetjournals.org/content/32/4/398.full.pdf
Web Search
http://dmd.aspetjournals.org/cgi/doi/10.1124/dmd.32.4.398
Publisher Site
http://dx.doi.org/10.1124/dmd.32.4.398DOI Listing
April 2004